Jefferies Starts Vaxcyte (PCVX) at Buy (Earlier)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BofA Securities Starts Vaxcyte (PCVX) at Buy
July 7, 2020 9:21 AM EDTBofA Securities analyst Jason Gerberry initiates coverage on Vaxcyte (NASDAQ: PCVX) with a Buy rating and a price target of $37.00.
The analyst cited three key reasons to like the stock: "1) Pneumococcal conjugate vaccine is the largest vaccine market with >$7bn/$8.5bn... More
UPDATE: Needham & Company Starts Vaxcyte (PCVX) at Buy
July 7, 2020 6:52 AM EDT(Updated - July 7, 2020 8:47 AM EDT)
(updated to add analyst comments)
Needham & Company analyst Alan Carr initiates coverage on Vaxcyte (NASDAQ: PCVX) with a Buy rating and a price target of $40.00.
The analyst commented, "Vaxcyte is leveraging a unique conjugation technology... More
UPDATE: Cantor Fitzgerald Starts Vaxcyte (PCVX) at Overweight
July 7, 2020 3:36 AM EDT(Updated - July 7, 2020 5:09 AM EDT)
(updating comment)
Cantor Fitzgerald analyst Louis Chen initiates coverage on Vaxcyte (NASDAQ: PCVX) with a Overweight rating and a price target of $55.00.
The analyst comments "We expect upward earnings forecast revisions and multiple... More
